The Best and Worst Mutual Funds of Q1 2013

Japan and healthcare were especially hot during the quarter

      View All  

#3 Best: Kinetics Medical

Kinetics185 The Best and Worst Mutual Funds of Q1 2013Q1 Return: +20.5%

Since 1999, Paul Abel has managed the Kinetics Medical Fund (MUTF:MEDRX), which focuses on pharma and biotech investments. These sectors were certainly red-hot in the latest quarter, and the fund was positioned nicely to capitalize on this.

Some of the fund’s top holdings were especially productive, such as Eli Lilly (NYSE:LLY, +15%), Pfizer (NYSE:PFE, +15%) and Novartis (NYSE:NVS, +12.5%).

Abel takes a long-term perspective on things, considering the time it can take to get drugs to approval. The fund is so long-term-focused, in fact, that MEDRX’s turnover ratio is listed as 0%.

Speaking of long-term, that’s also the time horizon of the fund’s past success. MEDRX has averaged nearly 9% annual returns since inception in 1999.


Article printed from InvestorPlace Media, http://investorplace.com/2013/03/the-best-and-worst-mutual-funds-of-q1-2013/.

©2014 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.